Assuntos
Neoplasias Esofágicas/complicações , Neoplasias Esofágicas/diagnóstico , Refluxo Laringofaríngeo/etiologia , Pólipos/diagnóstico , Endoscopia do Sistema Digestório , Neoplasias Esofágicas/patologia , Neoplasias Esofágicas/cirurgia , Humanos , Laringoscopia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Pólipos/complicações , Pólipos/patologia , Pólipos/cirurgiaAssuntos
Neoplasias dos Ductos Biliares/patologia , Ductos Biliares Intra-Hepáticos/patologia , Colangiocarcinoma/secundário , Colo/patologia , Neoplasias do Colo/secundário , Mucosa Intestinal/patologia , Biomarcadores Tumorais/análise , Colangiocarcinoma/química , Colo/química , Neoplasias do Colo/química , Colonoscopia , Feminino , Humanos , Imuno-Histoquímica , Mucosa Intestinal/química , Pessoa de Meia-Idade , Invasividade NeoplásicaRESUMO
Comparative studies of alternating non-cross resistant chemotherapy, A.V.N.-D.V.C. (ACNU + VCR + PCZ-ADM + VCR + CPA) was carried out on 19 patients with small cell lung cancer. A.V.N. (A. V.F.) therapy on 45 patients and D.V.C. therapy on 19 patients were used as historical control, respectively. A.V.N. (A.V.F.) therapy was composed of ACNU (2.5 mg/kg, day 1), VCR (0.02 mg/kg, once every week) and PCZ (1 mg/kg, daily) (or FT-207 (15 mg/kg, daily], and duration of one course was 6 to 8 weeks. D.V.C. therapy was composed of ADM (1 mg/kg, day 1) VCR (0.02 mg/kg, days 1 and 5) and CPA (2 mg/kg, days 1 to 5), and repeated every 4 weeks. A.V.N.-D.V.C. therapy was done by a timely alternation of one course of A.V.N. and two course of D.V.C. Reduction rate of tumor size was 84% in A.V.N.-D.V.C. therapy, 62% in A.V.N. (A.V.F.) therapy and 26% in D.V.C. therapy, respectively. Median survival time was 13 months on A.V.N.-D.N.C. therapy, 8.5 months and A.V.N. (A. V.F.) therapy and 4 months on D.V.C. therapy. Significant prolongation of median survival time was obtained in A.V.N.-D.V.C. therapy in comparison with that of historical controls. Major toxicity in A.V.N.-D.V.C. therapy was slight bone marrow suppression.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Esquema de Medicação , Humanos , Pessoa de Meia-Idade , Nimustina , Compostos de Nitrosoureia/administração & dosagem , Procarbazina/administração & dosagem , Vincristina/administração & dosagemRESUMO
A 57-year-old male was introduced to our hospital for his drug resistant non-ischemic ventricular tachycardia causing faintness attack. Preoperative electrophysiological studies led to a diagnosis of ventricular tachycardia originating from the right ventricular outflow tract. After ventriculotomy, an abnormal muscle band was noticed in the right ventricular outflow tract, which seemed to be a focus of tachycardia by endocardial mapping. Myocardial excision with the abnormal muscle band was performed. In addition to, cryoablation was performed surrounding this area. After the operation, the ventricular tachycardia disappeared completely. No antiarrhythmic drug have been required at 18 months postoperative months.